PX'Therapeutics SA, formerly called Protein'eXpert, has set up an additional biomanufacturing unit dedicated to producing therapeutic proteins and monoclonal antibodies in mammalian cells.
Millipore has acquired the remaining 60 per cent of its Indian joint venture (JV) to drive growth in the country which it views, along with the other BRICS nations, as a critical part of its strategy.
Sistemic is targeting the US by setting up an office in Boston, Mass, from which it will promote its services that use miRNA to identify and understand a compound’s activity in a simpler way than genomics or proteomics.
Icon is looking to expand its bioanalytical capacity in Asia, notably in China, and bolster its genomics, proteomics and cell-based assay capabilities, according to a VP who discussed diversification of the business.
The drug industry must “fundamentally change” how it sells products and make greater use of advanced analytics to measure performance, according to a report by Deloitte Consulting.
GEA Pharma Systems has extended its agency agreement with India’s Ace Technologies to include its range of lyophil freeze-dryers in a bid to further open up the market.
A five-day international anti-counterfeiting operation involving regulators, police and customs officials from 24 countries has resulted in the seizure of 167,000 counterfeit pills.
Just weeks after completing its billion dollar Wyeth takeover, US drug giant Pfizer has floated the idea of entering Japan’s $5.8bn (€3.9bn)-a-year generic drugs market in 2011 in a bid to further diversify its revenue streams.
A $150m (€100m) biologics manufacturing plant is being setup in Abu Dhabi to produce therapeutics for the Middle East and North Africa, according to the Khaleej Times.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Patheon, Pharmarama and Omnia Biologics.
The splitting up of MDS Pharma Services had little impact on the remaining business as there was limited integration anyway, according to a VP who detailed how the divestitures have allowed resources to be focused on core strengths.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Xoma and Watson Pharmaceuticals, plus a new role for Fred Hasaan.
PPD’s acquisition of Merck’s vaccine testing laboratory will give it a geographic location from which it can compete for business with its “number one competitor”, which is well established in the north east of the US.
Continued high demand for vaccine manufacturing technologies saw life sciences emerge as one of the few positives for industrial processing specialist Pall in Q1.
It is “legislative madness” to allow reimportation in the US, according to the chair of EAASM who spoke at AAPS about Europe’s “porous supply chain” and how it could affect the standard of medicines in the States.
PPD will work with J&J’s Belgian subsidiary, Janssen Pharmaceutica, on drugs for bowel, skin and lung diseases in a $330m in a deal announced yesterday.
US CRO PharmaNet will conduct early phase clinical trials of therapeutic cancer vaccines being developed by UK group Scancell under a contract announced yesterday.
Neurosurgeons have developed and used a novel intra-arterial (IA) technique to deliver Avastin (bevacizumab) directly into a malignant brain tumour, potentially administering a higher dose with reduced toxicity.
UK process technologies firm Reaxa has received a £146K (€164K) R&D grant from the Northwest Regional Development Agency (NWDA) to scale-up production of its EnCat nickel catalyst.
Phase Forward is moving towards offering integrated systems to meet pharma’s need to maximise cost effectiveness and deal with upcoming EDC market saturation, according to a SVP at the company.
Boehringer Ingelheim looks set for a significant windfall with results from Phase III trials indicating that its drug flibanserin can boost sexual desire in women, raising the prospect of a female equivalent to Pfizer’s Viagra.
Regulators, industry and academia must do more to close the knowledge gap created by a historic shortage of women in clinical trials, according to speakers at AAPS 2009.
The FDA encourages innovation in excipients to develop new drugs or improve approved therapeutics and IPEC is helping to drive acceptance of these novel products, according to BASF.
US contract manufacturing organisation (CMO) Catalent’s packaging facility in Dublin, Ireland has achieved ISO 15378:2006 under the ISO’s quality scheme.
US biotech Emergent BioSolutions has bought a manufacturing facility from Maryland’s MdBio Foundation is a bid to expand its production infrastructure.
WuXi PharmaTech’s operating income increased by 35 per cent in the third quarter, underpinned by strong growth in China-based laboratory services, but its manufacturing operations continue to struggle.
Spanish ingredient supplier Cafosa has launched a new directly compressible pharmaceutical excipient for medicated chewing gums that, it claims, can boost patient compliance.
Lonza is manufacturing GlaxoSmithKline’s (GSK) and Genmab’s antibody Arzerra (ofatumumab), which was recently approved by the FDA, under a long-term supply deal.
Regulatory enforcement efforts to tackle counterfeit and substandard APIs are in disarray, according to Guy Villax, CEO of Hovione, who spoke at AAPS about the scale of the problem.
Icon is currently planning to occupy over a third of the 100,000 sq ft redeveloped hospital in Manchester, UK, which is due to open in 2012 and will become a flagship site for the CRO.
Pharma’s increasing collaboration and budget cuts have made hosted software more attractive to companies, according to Symyx which has made its lab notebook available on this platform.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including multiple appointments at Almac and a new chairman at TranScrip Partners.
AAPS 2009 has drawn to a close but over the three days numerous trends and debates emerged, including the strategies CROs are using in the downturn, and we take a look at these in our conference round up.
Dow has used AAPS 2009 to launch an updated, digital version of its Keys to Chelation compilation, which allows to industry reference standard to be used more effectively, according to the company.
French drug delivery specialist Galenix has named DSM’s pharmaceutical products unit as its manufacturing and co-marketing partner as it continues to efforts build its global presence.
Parexel has entered into an alliance with Mortara Instrument to bolster its early phase cardiac safety capabilities and improve the assesment of new compounds.
US contract polymer maker Delivery Science has ramped up its formulation and analytical testing offering in a partnership with the University of Rhode Island’s (URI) College of Pharmacy.
Pfizer will close six R&D facilities in the US and the UK, reducing its global capacity by over a third following completion of its acquisition of Wyeth.